Introduction: Despite tremendous potential public health impact, little work has focused on development of evidence-based smoking cessation treatments for adolescents, including pharmacotherapies. No prior studies have explored the feasibility and safety of varenicline and bupropion XL, 2 potentially promising pharmacotherapies, as smoking cessation treatments in adolescents.
Methods: Treatment-seeking older adolescent smokers (ages 15-20) were randomized (double-blind) to varenicline (n = 15) or bupropion XL (n = 14), with 1-week titration and active treatment for 7 weeks. Structured safety, tolerability, and efficacy assessments (cotinine-confirmed 7-day point prevalence abstinence) were conducted weekly.
Results: There were no serious adverse events. Two participants discontinued bupropion XL due to adverse effects, and none discontinued varenicline. Over the course of treatment, participants receiving varenicline reduced from 14.1 ± 6.3 (mean ± SD) to 0.9 ± 2.1 cigarettes/day (CPD, 4 achieved abstinence), while those receiving bupropion XL reduced from 15.8 ± 4.4 to 3.1 ± 4.0 CPD (2 achieved abstinence).
Conclusions: These preliminary results support the feasibility and safety of conducting adequately powered, placebo-controlled efficacy studies of varenicline and bupropion XL for adolescent smoking cessation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265741 | PMC |
http://dx.doi.org/10.1093/ntr/ntr130 | DOI Listing |
Nicotine Tob Res
January 2025
Department of Population Health Sciences, University of Leicester, Leicester, UK.
Introduction: Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation may be associated with varenicline response, but to date no genome-wide association studies of varenicline response have been published.
Methods: In this study, we investigated the genetic contribution to varenicline effectiveness using two electronic health record-derived phenotypes.
Healthcare (Basel)
December 2024
Department of Health Administration, Gyeonggi University of Science and Technology, Gyeonggi 15073, Republic of Korea.
: Adolescent smoking can lead to various health problems including atherosclerosis and cardiovascular disease, making it more difficult to quit smoking during adulthood. This study aims to evaluate the effect of the ordinance by assessing adolescents' smoking cessation behaviors and environmental conditions, according to the "Ordinance for the Prevention of Child and Adolescent Smoking and Support for Smoking Cessation", which was enacted in 2019 in Gwangju City, South Korea, for the first time in the country. : The data for the analysis were obtained from the 2018 and 2021 Korea Youth Risk Behavior Survey.
View Article and Find Full Text PDFAnn LGBTQ Public Popul Health
December 2024
Department of Health Systems and Population Health, University of Washington, School of Public Health, Seattle, WA, USA.
The intersection between a minoritized sexual orientation identity and a U.S. military Veteran status places lesbian, gay, and bisexual (LGB) Veterans at increased risk for cigarette smoking.
View Article and Find Full Text PDFJTO Clin Res Rep
January 2025
Icahn School of Medicine at Mount Sinai, New York, New York.
Lung cancer remains a leading cause of cancer-related mortality globally and presents significant challenges in Egypt. In 2023, the first annual meeting of the Thoracic Oncology Multidisciplinary Faculty, organized by the Egyptian Cancer Research Network and the Egyptian Society of Respiratory Neoplasms, was held in Cairo, Egypt. The meeting aimed to address gaps in lung cancer management across Egypt and the broader Middle East and North Africa region.
View Article and Find Full Text PDFIntroduction: The impact of e-cigarette flavoring on e-cigarette uptake and switching to e-cigarettes among adults who smoke is critical to e-cigarette regulation in the United Sates. The purpose of this secondary analysis was to assess the impact of e-cigarette flavoring choice on e-cigarette uptake and changes in cigarette smoking in a large nationwide trial of e-cigarette provision in the United States.
Methods: A free four-week supply of e-cigarettes was provided with minimal instructions to use to adults who smoke (N = 427).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!